Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.

An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.

Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.

Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.

Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.